Lantheus Holdings, Inc
LNTH · Diagnostics · $6.6B
Powering up
Not on a screen at the moment — no base, so no pivot to draw. The price and volume are below.
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
The read
Lantheus Holdings, Inc is not on any of the screens right now. Its relative strength rating is 84, and it sits in Diagnostics.
Peers
Catalyst roadmap
Nothing dated in the next three months that we can ingest automatically.
Flagged by the market sweep
Nothing flagged for this company on the last market sweep.
In the news
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETsGlobeNewswire Inc. · 5 days agoRadioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - SNS InsiderGlobeNewswire Inc. · 12 days ago
Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.
Insiders
No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.
X-ray